Pain treatment in patients with renal insufficiency
DOI:
https://doi.org/10.12775/JEHS.2022.12.08.051Keywords
pain managment, renal insufficiency, chronic pain, renal failure, chronic kidney diseaseAbstract
Chronic pain is experienced by the majority of patients with renal insufficiency. Pain management in patients with chronic kidney disease is difficult because a significant part of painkillers is excreted through the kidneys, therefore side effects are more common among this population. The aim of this review is to draw attention to the available pain management options in patients with CKD based on an analysis of published articles. The following article is based on the literature found in the pubmed database. Treatment should include pharmacological, non-pharmacological methods and treatment of comorbidities, whereas patients should be carefully monitored for side effects and possible complications. More research is needed in this area.
References
Baker M, Perazella MA.: NSAIDs in CKD: Are They Safe? Am J Kidney Dis, 2020;76(4):546-557.
Benyamin R, Trescot AM, Datta S, et al.: Opioid complications and side effects. Pain Physician, 2008;11:105-20.
Bertolini A, Ferrari A, Ottani A, et al.: Paracetamol: new vistas of an old drug. CNS Drug Rev, 2006;12(3-4):250-75.
Bourbonnais FF, Tousignant KF.: Experiences of Nephrology Nurses in Assessing and Managing Pain in Patients Receiving Maintenance Hemodialysis. Nephrol Nurs J, 2020;47(1):37-44.
Breivik H, Ljosaa TM, Stengaard-Pedersen K, et al.: A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids. Scand J Pain, 2010;1(3):122-141.
Brintz CE, Cheatle MD, Dember LM, et al.: Nonpharmacologic Treatments for Opioid Reduction in Patients With Advanced Chronic Kidney Disease. Semin Nephrol, 2021;41(1):68-81.
Charakterystyka Produktu Leczniczego. https://www.polfawarszawa.pl/products/chpl/smpc-poltram-retard-2018-07pl.pdf
Cheikh Hassan HI, Brennan F, Collett G, et al.: Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. J Pain Symptom Manage,2015;49(4):782-9.
Cukor D, Saggi SJ, Ahmad R, et al.: Pain experienced by dialysis patients in two culturally diverse populations. Hemodial Int, 2019;23(4):510-512.
Dansie EJ, Turk DC.: Assessment of patients with chronic pain. Br J Anaesth, 2013;111(1):19-25.
Daubresse M, Alexander GC, Crews DC, et al.: Trends in Opioid Prescribing Among Hemodialysis Patients, 2007–2014. Am J Nephrol, 2019;49:20-31.
Davison SN.: Clinical Pharmacology Considerations in Pain Management in Patients with Advanced Kidney Failure. Clin J Am Soc Nephrol, 2019;14(6):917-931.
Davison SN, Jhangri GS.: Impact of pain and symptom burden on the health-related quality of life of hemodialysis patients. J Pain Symptom Manage, 2010 ;39(3):477-85.
Davison SN, Koncicki H, Brennan F: Pain in chronic kidney disease: A scoping review. Semin Dial, 2014; 27: 188–204.
Dąbrowska-Bender M, Dykowska G, Żuk W, et al.: The impact on quality of life of dialysis patients with renal insufficiency. Patient Prefer Adherence,2018;12:577-583
Dean L.: Codeine therapy and CYP2D6 genotype. -in- Pratt V, Mcleod H, Dean L, Malheiro A, Rubinstein W. (eds.): Medical Genetics Summaries, National Center for Biotechnology Information (US), 2017.
Dobrogowski J, Wordliczek J, Szczudlik A, et al.: Zasady stosowania silnie działających opioidów u pacjentów z bólem przewlekłym pochodzenia nienowotworowego - przegląd piśmiennictwa i zalecenia Polskiego Towarzystwa Badania Bólu, Polskiego Towarzystwa Neurologicznego i Polskiego Towarzystwa Medycyny Rodzinnej. Ból, 2015;16(3)6:7-28.
Dobrogowski J, Zajączkowska R, Woroń J, et al.: Opioidowe leki przeciwbólowe. -in- Leczenie bólu, Wordliczek J, Dobrogowski J, Wydawnictwo Lekarskie PZWL,Warszawa, 2017; 54-84.
Dowell D, Haegerich TM, Chou R.: CDC Guideline for Prescribing Opioids for Chronic Pain -United States. JAMA, 2016 ;315(15):1624-45.
Graczyk M, Krajnik M.: Stosowanie analgetyków nieopioidowych a przewlekła choroba nerek. Palliat. Med. Pract, 2013; 7, 3–4: 95–104.
Graczyk M, Zylicz Z.: Co powinniśmy wiedzieć o stosowaniu leków opioidowych u pacjentów z przewlekłą chorobą nerek? Medycyna Palliat. Med. Pract, 2007;1(2)54-60.
Guarino H, Fong C, Marsch LA, et al.: Web-Based Cognitive Behavior Therapy for Chronic Pain Patients with Aberrant Drug-Related Behavior: Outcomes from a Randomized Controlled Trial. Pain Med, 2018;19(12):2423–37.
Gunal AI, Ozalp G, Yoldas TK, et al.: Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant, 2004;19(12):3137–9.
Gunter BR, Butler KA, Wallace RL, et al.: Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther, 2017;42(1):27–38.
Harris TJ, Nazir R, Khetpal P, et al.: Pain, sleep disturbance and survival in hemodialysis patients. Nephrol Dial Transplant, 2012;27(2):758–65.
Hsu H-J, Wu I-W, Hsu K-H, et al.: The association between chronic musculoskeletal pain and clinical outcome in chronic kidney disease patients: a prospective cohort study. Ren Fail, 2019;41(1):257–66.
Ibrahim H, Oman Z, Schuelke M, et al.: Treatment of Gabapentin Toxicity With Peritoneal Dialysis: Assessment of Gabapentin Clearance. Am J Kidney Dis, 2017;70(6):878-880.
Ishida JH, McCulloch CE, Steinman MA, et al.: Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients. J Am Soc Nephrol, 2018;29(7):1970–8.
Ishida JH, McCulloch CE, Steinman MA, et al.: Opioid Analgesics and Adverse Outcomes among Hemodialysis Patients. Clin J Am Soc Nephrol, 2018;13(5):746–53.
Jackman RP, Purvis JM, Mallett BS.: Chronic nonmalignant pain in primary care. Am Fam Physician, 2008;78(10):1155–62.
Jawed A, Moe SM, Moorthi RN, et al.: Increasing Nephrologist Awareness of Symptom Burden in Older Hospitalized End-Stage Renal Disease Patients. Am J Nephrol, 2020;51(1):11–6.
Jhamb M, Abdel-Kader K, Yabes J, et al.: Comparison of Fatigue, Pain, and Depression in Patients With Advanced Kidney Disease and Cancer—Symptom Burden and Clusters. J Pain Symptom Manage, 2019;57(3):566–575.
Kienzler JL, Gold M, Nollevaux F.: Systemic Bioavailability of Topical Diclofenac Sodium Gel 1% Versus Oral Diclofenac Sodium in Healthy Volunteers. J Clin Pharmacol, 2010;50(1):50–61.
Kimmel PL, Fwu CW, Abbott KC, et al.: Opioid Prescription, Morbidity, and Mortality in United States Dialysis Patients. J Am Soc Nephrol, 2017;28(12):3658-3670.
Klinge M, Coppler T, Liebschutz JM, et al.: The assessment and management of pain in cirrhosis. Curr Hepatol Rep, 2018; 17(1):42-51.
Kreek MJ, Schecter AJ, Gutjahr CL, et al.: Methadone use in patients with chronic renal disease. Drug Alcohol Depend, 1980;5(3):197-205.
Król E, Rutkowski B.: Przewlekła choroba nerek – klasyfikacja, epidemiologia i diagnostyka. Forum Nefrologiczne, 2008;1(1):1-6.
Kurella M, Bennett WM, Chertow M.: Analgesia in patients with esrd: a review of available evidence. Am J Kidney Dis,2003;42:217-28.
Leese PT, Hubbard RC, Karim A, et al.: Effects of Celecoxib, a Novel Cyclooxygenase-2 Inhibitor, on Platelet Function in Healthy Adults: A Randomized, Controlled Trial. J Clin Pharmacol, 2000;40(2):124–32.
McCrae JC, Morrison EE, MacIntyre IM, et al.: Long-term adverse effects of paracetamol - a review. Br J Clin Pharmacol,2018;84(10):2218–30.
McQuay HJ, Tramèr M, Nye BA, et al.: A systematic review of antidepressants in neuropathic pain. Pain,1996;68(2-3):217-27.
Mercadante S, Ferrantelli A, Tortorici C, et al.: Incidence of Chronic Pain in Patients with End-Stage Renal Disease on Dialysis. J Pain Symptom Manage,2005;30(4):302–4.
Mersfelder TL, Nichols WH.: Gabapentin: Abuse, Dependence, and Withdrawal. Ann Pharmacother, 2016;50(3):229–33.
Muzaale AD, Daubresse M, Bae S, et al.: Benzodiazepines, Codispensed Opioids, and Mortality among Patients Initiating Long-Term In-Center Hemodialysis. Clin J Am Soc Nephrol, 2020;15(6):794–804.
Narabayashi M, Saijo Y, Takenoshita S, et al.: Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial. Jpn J Clin Oncol, 2008;38(4):296–304.
Narain T, Adcock L.: Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness. Canadian Agency for Drugs and Technologies in Health, 2018.
Nguyen T, Shoukhardin I, Gouse A.: Duloxetine Uses in Patients With Kidney Disease. Am J Ther, 2019;26(4):e516–9.
Niscola P, Scaramucci L, Vischini G, et al.: The use of major analgesics in patients with renal dysfunction. Curr Drug Targets, 2010;11(6): 752-8.
Opdal MS, Arnesen M, Müller LD, et al.: Effects of Hemodialysis on Methadone Pharmacokinetics and QTc. Clin Ther, 2015;37(7):1594-9.
O’Brien T, Ahn JS, Chye R, et al.: Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management. J Opioid Manag,2019;15(2):147-158.
Pham PC, Khaing K, Sievers TM, et al.: 2017 update on pain management in patients with chronic kidney disease. Clin Kidney J, 2017;10(5):688-697.
Porażka J, Karbownik A, Szałek E, et al.: Zmiany w farmakokinetyce analgetyków u pacjentów z niewydolnością nerek. Farm Wsól, 2015;8:1-9.
Przeklasa-Muszyńska A, Kocot-Kępska M, Woronicza J, et al.: Leczenie bólu u chorych z niewydolnością nerek – aspekty kliniczne. Medycyna bólu Terapia 2021, 7 (402 ):64 - 71.
Rauck RL, Potts J, Xiang Q, et al.: Efficacy and tolerability of buccal buprenorphine in opioid- naive patients with moderate to severe chronic low back pain. Postgrad Med, 2016;128(1):1–11.
Roy PJ, Weltman M, Dember LM, et al.: Pain management in patients with chronic kidney disease and end-stage kidney disease. Curr Opin Nephrol Hypertens,2020;29(6):671-680.
Searle A, Spink M, Ho A, et al.: Exercise interventions for the treatment of chronic low back pain: a systematic review and meta-analysis of randomised controlled trials. Clin Rehabil, 2015;29(12):1155–67.
Simon LS, Weaver AL, Graham DY, et al.: Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid Arthritis. JAMA,1999;282(20):1921
Simonsen E, Komenda P, Lerner B, et al.: Treatment of Uremic Pruritus: A Systematic Review. Am J Kidney Dis, 2017;70(5):638–55.
Sriperumbuduri S, Hiremath S.: The case for cautious consumption. Curr Opin Nephrol Hypertens, 2019;28(2):163–70.
Tegeder I, Lötsch J, Geisslinger G.: Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet, 1999;37(1):17-40.
Vangala C, Niu J, Montez-Rath ME, et al.: Hip Fracture Risk among Hemodialysis-Dependent Patients Prescribed Opioids and Gabapentinoids. J Am Soc Nephrol, 2020;31(6):1325-1334.
Velenosi TJ, Urquhart BL.: Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis. Expert Opin Drug Metab Toxicol, 2014;10(8):1131-43.
Waddy SP, Becerra AZ, Ward JB, et al.: Concomitant Use of Gabapentinoids with Opioids Is Associated with Increased Mortality and Morbidity among Dialysis Patients. Am J Nephrol, 2020;51(6):424-432.
Weisbord SD, Mor MK, Sevick MA, et al.: Associations of Depressive Symptoms and Pain with Dialysis Adherence, Health Resource Utilization, and Mortality in Patients Receiving Chronic Hemodialysis. Clin J Am Soc Nephrol, 2014; 9(9):1594–602.
Whelton A.: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med, 1999;106(5B):13S-24S.
WHO: WHO’s cancer pain ladder for adults, 2017 Available at: http://www.who.int/cancer/palliative/painladder/en/. Accessed September 14, 2018
Williams AC, Eccleston C, Morley S.: Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev, 2012;11(11):CD007407
Wongrakpanich S, Wongrakpanich A, Melhado K, et al.: A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly. Aging Dis, 2018;9(1):143-150.
Woroń J: Nieopioidowe leki przeciwbólowe w leczeniu bólu. -in- Kompendium Leczenia Bólu, Malec-Milewska M, Woroń J, Wydawca Medical Education,Warszawa, 2017;23-43.
Zajączkowska R, Woroń J, Krajnik Małgorzata et al.: Leczenie bólu u pacjentów z zaawansowaną niewydolnością narządową. -in- Leczenie bólu, Wordliczek J, Dobrogowski J, Wydawnictwo Lekarskie PZWL,Warszawa, 2017; 629-635.
Zhan M, Doerfler RM, Xie D, et al.: Association of Opioids and Nonsteroidal Anti-inflammatory Drugs With Outcomes in CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis,2020;76(2):184-193.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Jordi Gras-Ozimek, Urszula Kozinska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 2661
Number of citations: 0
